Internal standard high-performance liquid chromatography method for the determination of obidoxime in urine of organophosphate-poisoned patients

被引:29
作者
Grasshoff, C
Thiermann, H
Gillessen, T
Zilker, T
Szinicz, L
机构
[1] Inst Pharmakol & Toxikol, D-85748 Garching, Germany
[2] Tech Univ Munich, Klinikum Rechts Isar, Med Klin 2, Toxikol Abt, D-81664 Munich, Germany
来源
JOURNAL OF CHROMATOGRAPHY B | 2001年 / 753卷 / 02期
关键词
obidoxime; organophosphate;
D O I
10.1016/S0378-4347(00)00543-0
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Obidoxime is an antidote approved for reactivation of inhibited acetylcholinesterase in organophosphate poisoning. HPLC methods were described far its determination in blood or aqueous solutions but not for the determination in urine. Since data for renal obidoxime excretion ranged from 2.2 to 84% of administered dose in healthy volunteers depending on the route of administration and little is known about pharmacokinetics of obidoxime in severely intoxicated patients we developed an internal standard (HI 6) reversed-phase HPLC method for determining obidoxime in urine. The mobile phase consisted of methanol, the counter ion 1-heptane sulfonic acid and tetrabutylammonium phosphate, the stationary phase involved a 5 mum reversed-phase column (125x4 mm). Obidoxime was detected spectrophotometrically at 288 nm. The limit of quantification (LOQ) was 1 muM, the limit of detection (LOD) 0.5 muM. Linear calibration curves were obtained in a concentration range from 1 to 1000 muM. Intra- and inter-day precision C.V.s were below 4%. Accuracy was 95.9% in the LOQ range. Using this method, we were able to quantify obidoxime in urine of an organophosphate poisoned patient. Based on this data we calculated that 58% of the administered dose was excreted in the urine. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:203 / 208
页数:6
相关论文
共 16 条
[1]  
Bendayan R, 1996, PHARMACOTHERAPY, V16, P971
[2]   DETERMINATION OF SOME PYRIDINIUM ALDOXIME COMPOUNDS BY MEANS OF ION-PAIR REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY - APPLICATION IN BIOLOGICAL-MATERIAL [J].
BENSCHOP, HP ;
KONINGS, KAG ;
KOSSEN, SP ;
LIGTENSTEIN, DA .
JOURNAL OF CHROMATOGRAPHY, 1981, 225 (01) :107-114
[3]  
Eyer P., 1996, ROLE OXIMES TREATMEN, P33
[4]   VALIDATION OF BIOANALYTICAL METHODS [J].
KARNES, HT ;
SHIU, G ;
SHAH, VP .
PHARMACEUTICAL RESEARCH, 1991, 8 (04) :421-426
[5]   PHYSIOLOGIC IMPLICATIONS OF MECHANICAL VENTILATION ON PHARMACOKINETICS [J].
PERKINS, MW ;
DASTA, JF ;
DEHAVEN, B .
DICP-THE ANNALS OF PHARMACOTHERAPY, 1989, 23 (04) :316-323
[6]   DETERMINATION OF ATROPINE AND OBIDOXIME IN AUTOMATIC INJECTION DEVICES USED AS ANTIDOTES AGAINST NERVE AGENT INTOXICATION [J].
POHJOLA, J ;
HARPF, M .
JOURNAL OF CHROMATOGRAPHY A, 1994, 686 (02) :350-354
[7]  
SHAH VP, 1991, EUR J DRUG METAB PH, V16, P249
[8]   TOXOGONIN - BLOOD LEVELS AND SIDE EFFECTS AFTER INTRAMUSCULAR ADMINISTRATION IN MAN [J].
SIDELL, FR ;
GROFF, WA .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1970, 59 (06) :793-&
[9]   TOXOGONIN - ORAL ADMINISTRATION TO MAN [J].
SIDELL, FR ;
GROFF, WA .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1971, 60 (06) :860-&
[10]   TOXOGONIN AND PRALIDOXIME - KINETIC COMPARISON AFTER INTRAVENOUS ADMINISTRATION TO MAN [J].
SIDELL, FR ;
GROFF, WA ;
KAMINSKIS, A .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1972, 61 (11) :1765-+